SLN Stock Analysis: Buy, Sell, or Hold?
SLN - Silence Therapeutics Plc American Depository Share
$13.02
-0.29 (-2.18%)
▼
5d:
-11.97%
30d:
-4.12%
90d:
+94.91%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When SLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SLN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SLN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SLN is currently trading at $13.02, which is considered fair relative to its 30-day fair value range of $12.06 to $14.66.
Technical Outlook: Technically, SLN is in a strong uptrend. The price is currently testing key support at $12.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SLN scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.00 (+153.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SLN is in a strong uptrend. The price is currently testing key support at $12.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SLN scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.00 (+153.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$12.06 -
$14.66
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 153.5% below Wall St target ($33.00)
- CAUTION: 5-day price weakness (-12.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$12.06 -
$14.66
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$12.88
Resistance Level
$15.28
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-34.26
Wall Street Target
$33.00
(+153.5%)
Revenue Growth (YoY)
197.2%
Share & Embed Analysis
Last updated: September 13, 2026 7:40 AM ET
Data refreshes hourly during market hours. Next update: 8:40 AM
Data refreshes hourly during market hours. Next update: 8:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 50 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
